Routine immunohistochemical assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression in breast cancer holds great significance due to the critical prognostic and therapeutic implications of these biomarkers [3]. The gene discussed is PGR; the disease is breast carcinoma.